Regeneron Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSu...
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
- Conditions
- Interventions
- First Posted Date
- 2024-05-20
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 95
- Registration Number
- NCT06421636
- Locations
- 🇮🇳
Hemato-Oncology Clinic Ahmedabad PVT. LTD., Ahmedabad, Gujarat, India
🇲🇾Hospital Tunku Ampuan Besar Tuanku Aishah Rohani (HPKK UKM), Cheras, Kuala Lumpur, Malaysia
🇬🇪K Eristavi National Center of Experimental and Clinical Surgery, Tbilisi, Georgia
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
- Conditions
- Interventions
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 150
- Registration Number
- NCT06413680
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸START Midwest Cancer Research, Grand Rapids, Michigan, United States
🇺🇸The START Center for Cancer Care, San Antonio, Texas, United States
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 800
- Registration Number
- NCT06398080
Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)
- Conditions
- Interventions
- First Posted Date
- 2024-04-25
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Registration Number
- NCT06384820
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 130
- Registration Number
- NCT06379789
- Locations
- 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States
Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
- First Posted Date
- 2024-04-17
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT06369467
- Locations
- 🇺🇸
Emory University- Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
- Conditions
- Interventions
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT06351592
- Locations
- 🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇨🇦London Health Sciences Centre, London, Ontario, Canada
🇨🇦Montreal Neurological Hospital, McGill University, Montreal, Quebec, Canada
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
- Conditions
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 195
- Registration Number
- NCT06299111
- Locations
- 🇧🇬
SVETA Sofia Hospital, Sofia, Bulgaria
🇷🇴ARENSIA Exploratory Medicine Clinic at Country Hospital Cluj-Napoca, Cluj-Napoca, Romania
A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss
- Conditions
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 999
- Registration Number
- NCT06299098
- Locations
- 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇺🇸Cullman Clinical Trials, Cullman, Alabama, United States
🇺🇸Foothills Research Center/ CCT Research, Phoenix, Arizona, United States
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
- Conditions
- Interventions
- First Posted Date
- 2024-03-05
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 220
- Registration Number
- NCT06292780
- Locations
- 🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom
🇺🇸City of Hope, Duarte, California, United States
🇪🇸Universitary Hospital Son Espases, Palma, Balearic Islands, Spain